Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection.
about
Epidemiology and Recurrence Rates of Clostridium difficile Infections in Germany: A Secondary Data Analysis.Prediction of Recurrent Clostridium Difficile Infection Using Comprehensive Electronic Medical Records in an Integrated Healthcare Delivery System.Cadazolid for the treatment of Clostridium difficile.ECCMID 2016: addressing the burden of recurrent Clostridium difficile infections.A multi-center study of fidaxomicin use for Clostridium difficile infectionFidaxomicin for treatment of Clostridium difficile infection in clinical practice: a prospective cohort study in a French University Hospital.Rethinking Strategies to Select Antibiotic Therapy in Clostridium difficile infection.Antibodies to Toxin B Are Protective Against Clostridium difficile Infection Recurrence.Bezlotoxumab for the prevention of Clostridium difficile recurrence.Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.Distinguishing Clostridium difficile Recurrence From Reinfection: Independent Validation of Current Recommendations.High risk of post-infectious irritable bowel syndrome in patients with Clostridium difficile infection.The Impact of Recurrent Clostridium difficile Infection on Patients' Prevention Behaviors.Bezlotoxumab: an emerging monoclonal antibody therapy for prevention of recurrent Clostridium difficile infection.Impact of oral fidaxomicin administration on the intestinal microbiota and susceptibility to Clostridium difficile colonization in mice.Bezlotoxumab for prevention of recurrent C. difficile infection in patients at increased risk for recurrence.Thirty-Day Readmissions in Hospitalized Patients Who Received Bezlotoxumab With Antibacterial Drug Treatment for Clostridium difficile Infection.Novel Antimicrobials for the Treatment of Clostridium difficile Infection.Predictors of Mortality Among a National Cohort of Veterans With Recurrent InfectionNationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in TaiwanEnhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycinBezlotoxumab Is Associated With a Reduction in Cumulative Inpatient-Days: Analysis of the Hospitalization Data From the MODIFY I and II Clinical Trials
P2860
Q31138398-F9724AE5-8957-4E63-B079-5E07BC8B639CQ38611301-8353C27F-0EF9-41FD-ACA8-AC55615BE36AQ38746746-0308D53D-9762-4D91-A6C5-6F3EC6170531Q38816937-F32BEBBD-41F8-43DA-8328-6711CE1B88D9Q38930594-84E89ABE-FCEC-4B6D-9D16-AEAF24D4C808Q39000863-1F93F5BF-3CD3-4CF6-BA09-A81184A38631Q39175350-EB983018-F02F-4317-B097-68BDE55749F2Q39640585-0E3596EF-BB5D-4BC1-AA4C-6BE694D08F73Q40095035-628BCCB1-F82E-449D-88A7-D2B34C0E9D42Q40125340-44FA6CA4-A01F-4640-8B65-2C4F16A8C821Q40168493-CB2178B7-B1DA-46D6-B615-D93BFA9CD3D0Q40604510-210EF823-D6DD-4F3A-92A4-63AAE7693083Q41994402-A57E047D-4AB9-49C2-BB27-B950D1083B83Q49201152-D98D8004-20C7-484F-9CEA-8B2F46BBF4C5Q49792028-10D189B1-7E4D-4E2B-BA01-80918E0469D0Q51740247-17B0A616-DA89-4B92-A26D-35CB22E3684DQ55103812-344486ED-8E4B-4411-91B8-C4E97C82BEC5Q55405974-86845315-F61A-44BE-9786-53194D05CBE1Q57496117-ACF240FF-D1F0-41E2-9167-A0A7CB0EEA2EQ58777748-725937E7-6FAD-4255-88AE-9F776A26E64AQ58803847-E58B3D69-5382-4D3C-A1B0-FDAB15A7B508Q59126532-D981B153-86CD-41C6-AEEB-5114CC35D56B
P2860
Clinical and Healthcare Burden of Multiple Recurrences of Clostridium difficile Infection.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh
2015年學術文章
@zh-hant
name
Clinical and Healthcare Burden ...... ostridium difficile Infection.
@en
type
label
Clinical and Healthcare Burden ...... ostridium difficile Infection.
@en
prefLabel
Clinical and Healthcare Burden ...... ostridium difficile Infection.
@en
P2093
P2860
P356
P1476
Clinical and Healthcare Burden ...... ostridium difficile Infection.
@en
P2093
Anaïs Marcil-Héguy
Caroline Sheitoyan-Pesant
Claire Nour Abou Chakra
Jacques Pépin
Vincent Nault
P2860
P304
P356
10.1093/CID/CIV958
P407
P577
2015-11-17T00:00:00Z